ASMB (Assembly Biosciences) Cash Flow from Others: $-1.79 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASMB Assembly Biosciences Inc ASMB
32 GF Score
Price $26.68
! 3 Warning Signs
View Full Analysis

What is Assembly Biosciences Cash Flow from Others?

Assembly Biosciences ASMB 32 Cash Flow from Others is $-1.79 Mil as of Mar. 2026. GuruFocus rates ASMB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Assembly Biosciences's cash flow from others for the three months ended in Mar. 2026 was $-0.59 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.79 Mil.

Assembly Biosciences Cash Flow from Others Related Terms

Assembly Biosciences Cash Flow from Others Historical Data

* Premium members only.

The historical data trend for Assembly Biosciences's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Assembly Biosciences Cash Flow from Others Chart

Assembly Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Others
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.05 3.66 2.06 -2.24 -1.50

Assembly Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.29 -0.16 -0.42 -0.63 -0.59
ASMB
32GF Score
Assembly Biosciences Inc ASMB
Cash Flow from Others is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Assembly Biosciences Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.79 Mil.

Frequently Asked Questions Learn more about Cash Flow from Others →
What does a Cash Flow from Others of $-1.79 Mil mean?
Assembly Biosciences (ASMB) has a Cash Flow from Others of $-1.79 Mil as of Mar. 2026. Cash Flow from Others is the amount of cash earned or paid from other, nonstandard operations. View historical data for Assembly Biosciences and its competitors.
Is Assembly Biosciences' Cash Flow from Others too high?
Assembly Biosciences' current Cash Flow from Others is $-1.79 Mil. Overall, Assembly Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' Cash Flow from Others compare to ZURA and ARVN?
Assembly Biosciences' Cash Flow from Others of $-1.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Others for a Biotechnology company?
A good Cash Flow from Others depends on the Biotechnology industry context. However, Cash Flow from Others should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Others mean?
A high Cash Flow from Others can signal that a stock is expensive relative to its fundamentals. Cash Flow from Others is the amount of cash earned or paid from other, nonstandard operations. View historical data for Assembly Biosciences and its competitors. Assembly Biosciences's current Cash Flow from Others is $-1.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current Cash Flow from Others of $-1.79 Mil. The current Cash Flow from Others is $-1.79 Mil. Assembly Biosciences' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Others calculated?
Cash Flow from Others is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current Cash Flow from Others is $-1.79 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Assembly Biosciences Business Description

Other Exchanges V7B:Germany
Address Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
32GF Score

Get the complete analysis for ASMB

Cash Flow from Others is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.68
Price